Page 1

botanix PHARMACEUTICALS 30 April 2021 Botanix Pharmaceuticals Quarterly Activities Report and 4C Quarterly Cash Flow Report Key highlights • Botanix's data from its antimicrobial program published in Nature Research's Communications Biology , a leading peer - reviewed biological sciences journal • Top - line data in the BTX 1801 Phase 2a study showed two different BTX 1801 formulations were safe , well tolerated and successful at eradicating Staphylococcus Aureus . Ethics approval received for the commencement of the BTX 1702 Phase 1b clinical study for papulopustular rosacea , with expanded design expected to enrol first patients in Q2 CY2021 Management team enhanced with three key hires in the US to drive clinical and commercial activities across the antimicrobial and dermatology programs Botanix in a strong financial position , holding cash balance of A $ 23.3m as at 31 March 2021 Philadelphia PA and Perth Australia , 30 April 2021 : Clinical dermatology company , Botanix Pharmaceuticals Limited ( ASX : BOT , “ Botanix ” or “ the Company " ) , is pleased to release its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the period ended 31 March 2021 . Clinical development Antimicrobial platform : research data published and positive BTX 1801 Phase2a results announced In January 2021 , research data from Botanix's antimicrobial platform was published in Nature Research's peer - reviewed journal , Communications Biology . The article , " The antimicrobial potential of cannabidiol " represents the culmination of 2 years of research by Botanix and its collaborators including several leading international antimicrobial researchers , with all data generated fully - owned by Botanix and the subject of several patent applications . Notably , the article provided new insights into the mechanism of action by which cannabidiol works to kill bacteria as well as highlighting the discovery that cannabidiol can kill a subset of Gram - negative bacteria that includes the ' urgent threat ' pathogen Neisseria gonorrhoeae which causes gonorrhea , as well as the bacteria that cause meningitis and legionnaires disease respectively . In February 2021 , Botanix announced positive top - line data from its BTX 1801 Phase 2a nasal decolonisation clinical study . Results of the BTX 1801 study showed the two formulations ( ointment and gel ) of BTX 1801 met the study endpoints which were focused on safety and eradication of Staph Aureus in the nasal cavity of study participants with confirmed carriage of bacteria . BTX 1801 was found to be safe and well tolerated , with all 66 enrolled participants completing the study . The incidence of adverse events was low , mild in severity and occurred at similar rates across the different treatment groups , with no severe events reported . Secondly , efficacy of both ointment and gel formulations at the primary endpoint of Day 12 was demonstrated . The positive top - line data from the